The 10-day moving average for DXCM crossed bearishly below the 50-day moving average on October 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 73%.
DXCM moved below its 50-day moving average on October 16, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DXCM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 73%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 40 of 58 cases where DXCM's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 69%.
The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on DXCM as a result. In 61 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 69%.
The Moving Average Convergence Divergence (MACD) for DXCM just turned positive on October 16, 2026. Looking at past instances where DXCM's MACD turned positive, the stock continued to rise in 30 of 46 cases over the following month. The odds of a continued upward trend are 65%.
Following a +1.22% 3-day Advance, the price is estimated to grow further. Considering data from situations where DXCM advanced for three days, in 204 of 301 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
DXCM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Price Growth Rating for this company is 18 (best 1 - 100 worst), indicating outstanding price growth. DXCM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 27 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 27 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 72 (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.484) is normal, around the industry mean (10.930). P/E Ratio (34.261) is within average values for comparable stocks, (100.178). Projected Growth (PEG Ratio) (1.332) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (6.988) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DXCM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
The Aroon Indicator for NVST entered a downward trend on October 16, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 217 similar instances where the Aroon Indicator formed such a pattern. In 170 of the 217 cases the stock moved lower. This puts the odds of a downward move at 78%.
The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NVST as a result. In 74 of 108 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 69%.
The 50-day moving average for NVST moved below the 200-day moving average on October 14, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where NVST's RSI Oscillator exited the oversold zone, 18 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 67%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 69 cases where NVST's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 67%.
The Moving Average Convergence Divergence (MACD) for NVST just turned positive on October 06, 2026. Looking at past instances where NVST's MACD turned positive, the stock continued to rise in 33 of 51 cases over the following month. The odds of a continued upward trend are 65%.
Following a +3.75% 3-day Advance, the price is estimated to grow further. Considering data from situations where NVST advanced for three days, in 177 of 273 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.
NVST may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 56 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.239) is normal, around the industry mean (5.011). P/E Ratio (40.914) is within average values for comparable stocks, (163.451). Projected Growth (PEG Ratio) (0.020) is also within normal values, averaging (4.456). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (1.451) is also within normal values, averaging (56.074).
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating fairly steady price growth. NVST’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 83 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 87 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NVST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
DXCM | NVST | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 82 | 65 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 82 Overvalued | 56 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 27 | 87 | |
PRICE GROWTH RATING 1..100 | 18 | 59 | |
P/E GROWTH RATING 1..100 | 72 | 83 | |
SEASONALITY SCORE 1..100 | 27 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NVST's Valuation (56) in the null industry is in the same range as DXCM (82) in the Medical Specialties industry. This means that NVST’s stock grew similarly to DXCM’s over the last 12 months.
NVST's Profit vs Risk Rating (100) in the null industry is in the same range as DXCM (100) in the Medical Specialties industry. This means that NVST’s stock grew similarly to DXCM’s over the last 12 months.
DXCM's SMR Rating (27) in the Medical Specialties industry is somewhat better than the same rating for NVST (87) in the null industry. This means that DXCM’s stock grew somewhat faster than NVST’s over the last 12 months.
DXCM's Price Growth Rating (18) in the Medical Specialties industry is somewhat better than the same rating for NVST (59) in the null industry. This means that DXCM’s stock grew somewhat faster than NVST’s over the last 12 months.
DXCM's P/E Growth Rating (72) in the Medical Specialties industry is in the same range as NVST (83) in the null industry. This means that DXCM’s stock grew similarly to NVST’s over the last 12 months.
| DXCM | NVST | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 67% |
| Stochastic ODDS (%) | 1 day ago 69% | 1 day ago 67% |
| Momentum ODDS (%) | 1 day ago 69% | 1 day ago 69% |
| MACD ODDS (%) | 1 day ago 65% | 1 day ago 65% |
| TrendWeek ODDS (%) | 1 day ago 67% | 1 day ago 71% |
| TrendMonth ODDS (%) | 1 day ago 74% | 1 day ago 71% |
| Advances ODDS (%) | 9 days ago 68% | 2 days ago 65% |
| Declines ODDS (%) | 3 days ago 73% | 4 days ago 69% |
| BollingerBands ODDS (%) | 1 day ago 53% | 1 day ago 64% |
| Aroon ODDS (%) | N/A | 1 day ago 78% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
DXCM’s FA Score shows that 2 FA rating(s) are green while NVST’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
DXCM’s TA Score shows that 5 TA indicator(s) are bullish while NVST’s TA Score has 5 bullish TA indicator(s).
DXCM (@Medical/Nursing Services) experienced а +2.29% price change this week, while NVST (@Pharmaceuticals: Other) price change was -0.43% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -6.10%. For the same industry, the average monthly price growth was -8.07%, and the average quarterly price growth was -16.10%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -1.71%. For the same industry, the average monthly price growth was -3.86%, and the average quarterly price growth was +3.30%.
DXCM is expected to report earnings on Oct 29, 2026.
NVST is expected to report earnings on Nov 04, 2026.
The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Pharmaceuticals: Other (-1.71% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| IAK | 145.69 | 2.17 | +1.51% |
| iShares U.S. Insurance ETF (IAK) | |||
| SEPM | 33.44 | -0.05 | -0.15% |
| FT Vest U.S. Equity Max Buffer ETF - September (SEPM) | |||
| HFXI | 36.34 | -0.19 | -0.52% |
| NYLIM FTSE International Equity Currency Neutral ETF (HFXI) | |||
| PFO | 8.54 | -0.07 | -0.81% |
| Flaherty & Crumrine Preferred and Income Opportunity Fund | |||
| NVDB | 29.61 | -0.90 | -2.95% |
| ProShares Ultra NVDA (NVDB) | |||
A.I.dvisor indicates that over the last year, NVST has been closely correlated with ALGN. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if NVST jumps, then ALGN could also see price increases.
| Ticker / NAME | Correlation To NVST | 1D Price Change % | ||
|---|---|---|---|---|
| NVST | 100% | -2.55% | ||
| ALGN - NVST | 70% Closely correlated | -1.36% | ||
| XRAY - NVST | 60% Loosely correlated | -2.94% | ||
| BIO - NVST | 57% Loosely correlated | -3.05% | ||
| A - NVST | 55% Loosely correlated | -1.47% | ||
| MTD - NVST | 52% Loosely correlated | -1.02% | ||
More | ||||